Myriad Genetics, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Samraat S Raha
- Full Time Employees
- 2,700
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 322 North 2200 West Salt Lake City UT United States of America 84116
- IPO Date
- Oct 6, 1995
- CIK
- 0000899923
- Website
- myriad.com
- Similar Companies
- Business
- Myriad Genetics, Inc. (MYGN) operates as a leading molecular diagnostic testing and precision medicine company focused on hereditary cancer, reproductive health, oncology, urology, and mental health genetic testing; its core products include the myRisk Hereditary Cancer Test assessing risk for 11 major cancers across 63 genes, Prequel Prenatal Screen for chromosomal abnormalities like trisomies 21, 18, and 13, Foresight Carrier Screen for over 270 inherited conditions, GeneSight Psychotropic Test covering 61 medications for depression, anxiety, and ADHD, and Precise Oncology solutions such as molecular residual disease testing. Founded in 1991 and headquartered in Salt Lake City, Utah, the company employs proprietary technologies to analyze biological samples like blood or saliva, providing physicians and patients with actionable insights for disease risk prediction, treatment guidance, and progression assessment across the United States and internationally. Recent developments include a September 2025 strategic collaboration with SOPHiA GENETICS to develop companion diagnostics for liquid biopsy-based therapy selection, partnerships with GlaxoSmithKline for HRD testing in ovarian cancer, QIAGEN for distributable HRD tests, National Cancer Center Hospital East in Japan for molecular residual disease studies, PATHOMIQ for AI-enabled prostate cancer testing, and Clairity with MagView for an integrated AI-genetic risk platform in breast health; additionally, the company expanded its MyRisk panel, launched FirstGene combined prenatal screening, secured a $200 million senior secured term loan from OrbiMed in 2025 to support growth, and reported oncology volume increases alongside Q3 2025 financial results emphasizing product launches and commercial investments.
MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Dimensional Fund Advisors LP Reduces Stake in Myriad Genetics, Inc. $MYGN
Assenagon Asset Management S.A. Reduces Holdings in Myriad Genetics, Inc. $MYGN
Reviewing Dyadic International (NASDAQ:DYAI) and Myriad Genetics (NASDAQ:MYGN)
Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky
Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky
MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law
MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law
MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. on Behalf of Myriad Stockholders and Encourages Investors to Contact the Firm
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Myriad Genetics (MYGN)
MYRIAD GENETICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
MYGN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Myriad Genetics (MYGN)
Myriad Genetics, Inc. (MYGN) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel
Myriad Genetics, Inc. (MYGN) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel
Myriad Genetics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Myriad Genetics (MYGN)
Myriad Genetics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Myriad Genetics (MYGN)
Myriad Genetics, Inc. (MYGN) Q2 2026 Earnings Call Transcript
Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates
Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability
Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026